Literature DB >> 4593139

Combined drug and immunostimulation therapy against a syngeneic murine leukemia.

J W Pearson, M A Chirigos, S D Chaparas, N A Sher.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1974        PMID： 4593139     DOI： 10.1093/jnci/52.2.463

Source DB:  PubMed          Journal:  J Natl Cancer Inst        ISSN： 0027-8874            Impact factor:   13.506


× No keyword cloud information.
  4 in total

1.  Phase I study of MVE-2 evaluating toxicity and biologic response modification capability.

Authors:  J D Hainsworth; J T Forbes; W W Grosh; F A Greco
Journal:  Cancer Immunol Immunother       Date:  1986       Impact factor: 6.968

2.  Phase II trial of MVE-II in metastatic malignant melanoma.

Authors:  J Rinehart; J LaForge; D Gochnour; J Neidhart
Journal:  Cancer Immunol Immunother       Date:  1987       Impact factor: 6.968

3.  Stimulated autoantibody response and increased longevity in NZB/NZW mice treated with cyclophosphamide and tilorone.

Authors:  S E Walker; M R Anver
Journal:  Clin Exp Immunol       Date:  1978-09       Impact factor: 4.330

4.  Analysis of synergy between cyclophosphamide therapy and immunity against a mouse tumour.

Authors:  D M Chassoux; F M Gotch; I C MacLennan
Journal:  Br J Cancer       Date:  1978-08       Impact factor: 7.640
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.